Tiziana reports up to 34% drop in brain inflammation in third MSA patient on intranasal foralumab in Phase 2 trial

Reuters2026/07/31 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tiziana Life Sciences reported Phase 2 PET imaging results from a third multiple system atrophy patient treated with intranasal foralumab.
The results have already been presented as quantitative scan comparisons showing reduced brain inflammatory activity in regions linked to the disease.
The new readout broadly matches earlier signals in the first two treated patients, supporting repeatable biological activity across patients.
The group plans to treat additional patients to validate the imaging findings and further assess the therapy’s potential in MSA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310700OMX_____CNEWS_EN_GNW9801562_en) on July 31, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tiziana reports up to 34% drop in brain inflammation in third MSA patient on intranasal foralumab in Phase 2 trial

You may also like

Crypto prices